Long-term melatonin use for insomnia was associated with a higher hazard of heart failure (HF), an increase in HF hospitalizations and a doubling of all-cause mortality over five years, according to a ...

Please note: the ACC uses a January - December calendar, which is indicated in the estimated release dates below. The policies appear in order based on their estimated release date.

The Centers for Medicare and Medicaid Services (CMS) has released the 2026 Medicare Physician Fee Schedule (PFS) proposed rule, updating the PFS conversion factor from $32.3465 to $33.5875 for ...

Beta-blocker therapy following myocardial infarction (MI) was the primary focus of a hot line session at ESC Congress 2025. Study investigators presented findings from the REBOOT-CNIC and ...

The U.S. Food and Drug Administration (FDA) announced on May 1 that the Apple Atrial Fibrillation (AFib) History Feature now qualifies as a Medical Device Development Tool (MDDT) to assess AFib burden ...

Between 2% to 3% of all patients and 5% to 6% of all women who present with what looks like an acute coronary syndrome (ACS) are actually suffering from a peculiar and reversible acute cardiac ...

The U.S. Food and Drug Administration (FDA) has approved the FARAPULSE Pulsed Field Ablation System for isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, ...

Digitoxin in addition to guideline-directed medical therapy, reduced the risk of a composite of all-cause death and hospitalization for worsening heart failure (HF) among patients with advanced HF and ...

Food supplementation for patients following a heart failure (HF)-related hospitalization was both feasible and acceptable and associated with clinically meaningful improvement in quality of life ...

Using real-world outcomes data from the STS/ACC TVT Registry, findings from the EVOQUE study presented at TCT 2025 demonstrate favorable safety and effectiveness of transcatheter tricuspid valve ...

Mavacamten did not significantly improve exercise capacity as assessed by peak oxygen uptake or improve patient-reported health status compared with placebo in patients with symptomatic nonobstructive ...

The SGLT2 inhibitor empagliflozin did not lower the risk of a first hospitalization for heart failure (HF) or death from any cause among patients with an increased risk for HF following acute ...